Ciliary neurotrophic factor

Drug Profile

Ciliary neurotrophic factor

Latest Information Update: 09 Sep 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fidia Farmaceutici; Roche Palo Alto LLC
  • Developer Roche Palo Alto LLC
  • Class Eye disorder therapies; Obesity therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 09 Sep 1997 Dompe Biotec has terminated the licensing agreement with Fidia for ciliary neurotrophic factor in Italy
  • 11 Feb 1997 A study has been added to the adverse events section
  • 23 May 1995 Dompe Biotec is a licensee for ciliary neurotrophic factor in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top